title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Stocks That Hit 52-Week Lows On Monday,20220613T161842,https://www.benzinga.com/markets/options/22/06/27677156/52-weeks-high-and-low-article,HZNP,0.005366,Neutral,-0.001317
"Why Horizon Therapeutics Shares Are Trading Higher By Over 30%; Here Are 32 Stocks Moving Premarket - Akanda  ( NASDAQ:AKAN ) , Aspen Aerogels  ( NYSE:ASPN ) ",20221130T124216,https://www.benzinga.com/news/22/11/29903371/why-horizon-therapeutics-shares-are-trading-higher-by-over-30-here-are-32-stocks-moving-premarket,HZNP,0.110462,Neutral,-0.095337
MIMEDX Welcomes Kate Surdez as Chief Human Resources Officer,20220718T133523,https://www.benzinga.com/pressreleases/22/07/g28100211/mimedx-welcomes-kate-surdez-as-chief-human-resources-officer,HZNP,0.06623,Neutral,0.078346
MIMEDX Welcomes Kate Surdez as Chief Human Resources Officer,20220718T133500,https://www.globenewswire.com/news-release/2022/07/18/2481141/0/en/MIMEDX-Welcomes-Kate-Surdez-as-Chief-Human-Resources-Officer.html,HZNP,0.069094,Neutral,0.080586
Nasdaq Surges Over 300 Points; Moderna Earnings Beat Expectations,20220803T183340,https://www.benzinga.com/news/earnings/22/08/28338722/nasdaq-surges-over-300-points-moderna-earnings-beat-expectations,HZNP,0.0864,Neutral,0.026543
Dow Jumps 350 Points; Crude Oil Drops Over 2%,20220803T160010,https://www.benzinga.com/news/earnings/22/08/28335749/dow-jumps-350-points-crude-oil-drops-over-2,HZNP,0.093108,Neutral,0.027086
"Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial",20220803T141314,https://www.benzinga.com/general/biotech/22/08/28331170/biotech-daily-mercks-two-combo-cancer-trials-miss-main-goal-approval-for-sinovacs-covid-19-shot-f,HZNP,0.098659,Neutral,0.0
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated - Biogen  ( NASDAQ:BIIB ) ,20230728T155617,https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33444357/reatas-acquisition-fits-biogens-strategy-despite-high-cost-analyst-says-high-level-,HZNP,0.280615,Neutral,0.0
